218 related articles for article (PubMed ID: 36226405)
1. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
2. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
3. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.
Pitoia F; Jerkovich F; Urciuoli C; Schmidt A; Abelleira E; Bueno F; Cross G; Tuttle RM
Thyroid; 2015 Nov; 25(11):1235-42. PubMed ID: 26132983
[TBL] [Abstract][Full Text] [Related]
4. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
J Clin Endocrinol Metab; 2020 Mar; 105(3):e457-65. PubMed ID: 31665318
[TBL] [Abstract][Full Text] [Related]
6. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.
Trimboli P; Piccardo A; Signore A; Valabrega S; Barnabei A; Santolamazza G; Di Paolo A; Stati V; Chiefari A; Vottari S; Simmaco M; Ferrarazzo G; Ceriani L; Appetecchia M; Giovanella L
Thyroid; 2020 May; 30(5):713-719. PubMed ID: 31973653
[No Abstract] [Full Text] [Related]
7. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
8. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
[No Abstract] [Full Text] [Related]
9. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
11. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients.
Grani G; Zatelli MC; Alfò M; Montesano T; Torlontano M; Morelli S; Deandrea M; Antonelli A; Francese C; Ceresini G; Orlandi F; Maniglia CA; Bruno R; Monti S; Santaguida MG; Repaci A; Tallini G; Fugazzola L; Monzani F; Giubbini R; Rossetto R; Mian C; Crescenzi A; Tumino D; Pagano L; Pezzullo L; Lombardi CP; Arvat E; Petrone L; Castagna MG; Spiazzi G; Salvatore D; Meringolo D; Solaroli E; Monari F; Magri F; Triggiani V; Castello R; Piazza C; Rossi R; Ferraro Petrillo U; Filetti S; Durante C
Thyroid; 2021 Feb; 31(2):264-271. PubMed ID: 32475305
[No Abstract] [Full Text] [Related]
12. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
[No Abstract] [Full Text] [Related]
13. Dynamic Risk Stratification for Predicting Long-term Outcomes in Pediatric Differentiated Thyroid Cancers.
Majeed AK; Satapathy S; Ballal S; Bal C
J Clin Endocrinol Metab; 2023 May; 108(6):e208-e215. PubMed ID: 36577747
[TBL] [Abstract][Full Text] [Related]
14. Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma.
Moore MD; Postma E; Gray KD; Ullmann TM; Hurley JR; Goldsmith S; Sobel VR; Schulman A; Scognamiglio T; Christos PJ; Hassett E; Luick J; Whitehall D; Zarnegar R; Fahey TJ
World J Surg; 2018 Feb; 42(2):343-349. PubMed ID: 29058064
[TBL] [Abstract][Full Text] [Related]
15. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma.
Jeon MJ; Kim WG; Park WR; Han JM; Kim TY; Song DE; Chung KW; Ryu JS; Hong SJ; Shong YK; Kim WB
Eur J Endocrinol; 2014 Jan; 170(1):23-30. PubMed ID: 24088549
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the impact of 2015 American Thyroid Association guidelines in management of differentiated thyroid cancer patients.
Choudhury S; Agrawal A; Pantvaidya G; Shah S; Purandare N; Puranik A; Rangarajan V
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):547-553. PubMed ID: 31707429
[TBL] [Abstract][Full Text] [Related]
17. Practical Performance of the 2015 American Thyroid Association Guidelines for Predicting Tumor Recurrence in Patients with Papillary Thyroid Cancer in South Korea.
Lee SG; Lee WK; Lee HS; Moon J; Lee CR; Kang SW; Jeong JJ; Nam KH; Chung WY; Jo YS; Lee J
Thyroid; 2017 Feb; 27(2):174-181. PubMed ID: 27750028
[TBL] [Abstract][Full Text] [Related]
18. Referral Practice for Radioactive Iodine Ablation (RAI) after ATA guidelines 2015: results from a Tertiary Cancer Care Centre.
Dhar H; Thiagarajan S; Yousuf A; Nayyar SS; Chaukar D
Eur Arch Otorhinolaryngol; 2020 Sep; 277(9):2521-2526. PubMed ID: 32240364
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Thyroid Cancer: Postoperative Classifications and Response to Initial Therapy as Prognostic Factors.
Lazar L; Lebenthal Y; Segal K; Steinmetz A; Strenov Y; Cohen M; Yaniv I; Yackobovitch-Gavan M; Phillip M
J Clin Endocrinol Metab; 2016 May; 101(5):1970-9. PubMed ID: 26930182
[TBL] [Abstract][Full Text] [Related]
20. Radioactive iodine ablation post differentiated thyroid cancer surgery: an analysis of use and impact of the American Thyroid Association guidelines.
Sia Y; Dave RV; Nour D; Miller JA; Skandarajah AR; Tasevski R
ANZ J Surg; 2019 Nov; 89(11):E502-E506. PubMed ID: 31674140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
